Last updated: October 10, 2026
Optiray 300 is a mature, low-osmolar iodinated contrast agent containing ioversol at 300 mg iodine/mL. Its commercial position depends on hospital purchasing, radiology procedure volumes, supply reliability, and price competition rather than patent exclusivity. Guerbet is the principal commercial owner associated with the Optiray franchise in the United States. Product-level revenue is not publicly reported, so financial analysis must rely on Guerbet’s broader contrast-media results and portfolio disclosures.
What is Optiray 300 and how is it used?
Optiray 300 is an injectable radiographic contrast medium used to enhance computed tomography, angiography, digital subtraction angiography, and other diagnostic imaging procedures. It is administered intravenously or intra-arterially, depending on the indication and procedure.
| Attribute |
Optiray 300 |
| Active ingredient |
Ioversol |
| Strength |
300 mg iodine/mL |
| Dosage form |
Sterile injectable solution |
| Therapeutic category |
Iodinated X-ray contrast medium |
| Primary users |
Hospitals, imaging centers, radiology departments |
| Administration |
Intravenous and intra-arterial |
| Regulatory pathway |
FDA-approved prescription drug |
| Key competing products |
Isovue 300, Omnipaque 300, Visipaque, Ultravist |
| Commercial owner associated with U.S. franchise |
Guerbet |
| Market status |
Mature branded product competing in a multi-source market |
Optiray 300 is not a therapeutic drug taken chronically by patients. Demand is procedure-driven. Volumes rise with CT scans, angiography, cardiac imaging, and emergency-department diagnostics. Revenue is affected by hospital contracts and procedure reimbursement rather than prescription refills.
What is the FDA regulatory status of Optiray 300?
Optiray 300 is an FDA-approved ioversol injection product. The FDA-approved labeling identifies ioversol as a nonionic, low-osmolar contrast agent used for specified radiographic examinations.
The product’s commercial value is supported by regulatory approval, manufacturing capability, clinical familiarity, and hospital formulary placement. Those factors matter more than exclusivity because ioversol and competing iodinated contrast products have been marketed for decades.
The principal regulatory risks are manufacturing interruptions, quality deviations, facility constraints, and supply shortages. Contrast agents are sterile injectable products, making production and quality controls more demanding than for ordinary oral tablets.
What is the Orange Book status of Optiray 300?
Optiray 300 is a mature small-molecule injectable product. Any original composition, formulation, or use patents associated with its initial development would generally be expected to have expired after the standard U.S. patent term.
The commercial franchise therefore does not depend on a current, broad patent monopoly. Orange Book relevance is limited to any active listed patents, regulatory exclusivities, or later-approved product improvements. No widely recognized current patent barrier has established Optiray 300 as a protected, single-source product.
| Exclusivity factor |
Commercial assessment |
| Original compound exclusivity |
Expired |
| Original formulation exclusivity |
Expected to be expired |
| Current regulatory exclusivity |
Not a principal market barrier |
| Orange Book significance |
Limited relative to manufacturing and contracting |
| Paragraph IV exposure |
Low strategic significance unless tied to a later patent |
| Generic entry risk |
High in principle, but entry depends on FDA approval and supply economics |
The absence of meaningful current patent protection does not guarantee rapid generic entry. Injectable contrast products require validated sterile manufacturing, regulatory approval, supply contracts, and acceptable pharmacovigilance systems.
When does Optiray 300 lose exclusivity?
Optiray 300 has already lost practical exclusivity in the United States. Its market is mature, and competing iodinated contrast products are available from multiple manufacturers.
The relevant commercial question is not the expiration date of an original patent. It is whether a competitor can obtain approval, manufacture consistently, and win hospital contracts at a price that supports market entry.
For mature injectable products, competition can develop through:
- Approved generic ioversol injections.
- Authorized or relabeled products.
- Hospital purchasing organizations.
- Portfolio contracts covering several contrast agents.
- Substitution among clinically comparable agents.
The principal barriers are technical and commercial. They include sterile filling capacity, raw-material sourcing, regulatory inspections, container-closure systems, and distribution reliability.
How strong is the Optiray 300 patent estate?
The current patent estate appears commercially weak when measured against newer specialty drugs. Optiray 300 is an established contrast product with no apparent active, broad-based patent moat supporting premium pricing.
Patent strength can still exist in narrow areas, including:
- Specific container or vial configurations.
- Prefilled syringe systems.
- Automated injector compatibility.
- Packaging and stability methods.
- Manufacturing processes.
- Device-drug combinations.
- Particular diagnostic uses.
Those rights would usually protect a delivery system, process, or product configuration rather than the underlying ioversol molecule across all uses.
The practical protection for Optiray 300 comes from operational execution. A manufacturer with validated facilities and dependable supply can retain business even when the active ingredient is no longer patent-protected.
What formulations and delivery systems are protected?
The core Optiray 300 formulation is an aqueous ioversol solution containing 300 mg iodine/mL. Commercial differentiation can arise from packaging, concentration, presentation, and compatibility with imaging equipment.
Relevant commercial variables include:
| Variable |
Market effect |
| 50 mL, 100 mL, 125 mL, or larger presentations |
Determines procedure fit and waste |
| Vial versus prefilled syringe |
Affects labor, handling, and injector workflow |
| 300 mg iodine/mL concentration |
Supports selected CT and angiographic protocols |
| Container-closure configuration |
Affects stability and procurement |
| Bulk packaging |
Can reduce per-procedure cost in high-volume departments |
| Injector compatibility |
Can influence conversion costs and hospital preference |
Any patent protection for these attributes would be narrower than protection for the active pharmaceutical ingredient. Hospital purchasing decisions also tend to favor products that integrate with existing injectors and standard operating procedures.
Which companies compete with Optiray 300?
Optiray 300 competes in the global iodinated contrast-media market, where the principal suppliers include Guerbet, GE HealthCare, Bracco, Bayer, and generic manufacturers.
| Company |
Representative product |
Active ingredient |
| Guerbet |
Optiray |
Ioversol |
| Bracco |
Isovue |
Iopamidol |
| GE HealthCare |
Omnipaque |
Iohexol |
| Bayer |
Ultravist |
Iopromide |
| Guerbet |
Xenetix in selected markets |
Iobitridol |
| Various generic manufacturers |
Generic iodinated contrast products |
Multiple ingredients |
Optiray 300 does not compete only against generic ioversol. Hospitals can switch between chemically different low-osmolar contrast agents when clinical protocols, contracts, injector systems, and supply conditions permit.
This creates cross-product substitution. A shortage affecting one supplier can shift volume to another agent. Conversely, a supplier with a lower price or stronger availability can gain share without changing the underlying imaging procedure.
What market dynamics determine Optiray 300 sales?
Imaging procedure volumes
Demand is linked to CT, angiography, vascular imaging, and emergency diagnostics. Population aging, cardiovascular disease, cancer monitoring, and expanded imaging capacity support long-term procedure demand.
Revenue growth is limited by the maturity of the product and by the fact that contrast is a consumable tied to each imaging procedure. It does not generate recurring patient prescriptions.
Hospital purchasing pressure
Hospitals and group purchasing organizations negotiate contrast-media prices aggressively. A contract award can move significant volume between products. Price, availability, rebate terms, injector compatibility, and clinical familiarity all influence purchasing.
Supply reliability
Sterile injectable manufacturing creates a supply advantage for established suppliers. A manufacturer with reliable production can preserve share during shortages. A manufacturer with a plant interruption can lose volume quickly because hospitals must maintain procedure schedules.
Product mix
The 300 mg iodine/mL presentation competes with 320 and 350 mg iodine/mL products. Choice depends on protocol, image quality, renal-risk considerations, procedure type, and institutional practice.
Contrast shortage events
U.S. contrast shortages have demonstrated the market’s dependence on concentrated manufacturing networks. The 2022 shutdown of a GE HealthCare contrast manufacturing facility in Shanghai disrupted supply of iohexol products and caused hospitals to ration or substitute contrast media. Such events can temporarily increase demand for competing brands, including ioversol products (U.S. Food and Drug Administration, 2022).
What is the financial trajectory of Optiray 300?
Optiray 300 is likely a stable or declining mature-brand revenue contributor rather than a high-growth pharmaceutical asset. Guerbet reports financial performance at the company or business-segment level and does not generally disclose standalone global revenue for Optiray 300.
The expected trajectory has four phases:
| Period |
Financial profile |
| Initial launch |
Premium pricing supported by innovation and regulatory approval |
| Market development |
Volume expansion as hospitals adopt the product |
| Mature branded phase |
Stable procedure-linked sales with contracting pressure |
| Post-exclusivity phase |
Price erosion, substitution, and portfolio-management pressure |
The product can remain economically useful after patent expiry because:
- Contrast demand is recurring with each imaging procedure.
- Manufacturing and regulatory barriers limit the number of credible suppliers.
- Hospitals value continuity of supply.
- Switching products can require protocol review, staff training, and inventory changes.
- The brand can be included in broader Guerbet portfolio contracts.
The main financial pressures are price compression, generic competition, hospital consolidation, tender-based purchasing, and the availability of alternative contrast agents.
Guerbet’s broader financial performance is more informative than Optiray-specific revenue. The company operates across contrast agents, imaging systems, and related products. Its results therefore reflect portfolio mix, foreign-exchange movements, procedure volumes, pricing, and supply costs rather than the performance of Optiray 300 alone (Guerbet, 2023).
What generic entry risks exist for Optiray 300?
Generic entry risk is structurally high because ioversol is an old, well-characterized small molecule without a visible broad patent barrier. Entry is constrained by the requirements for sterile injectable production and FDA approval.
A credible generic entrant would need to address:
- Pharmaceutical equivalence.
- Sterility assurance.
- Container-closure integrity.
- Stability data.
- Manufacturing validation.
- Process controls for an injectable solution.
- FDA inspection readiness.
- Commercial-scale supply.
- Hospital and group-purchasing contracts.
Generic entry would likely cause gradual price erosion rather than an immediate collapse in branded volume. Hospitals may continue purchasing branded Optiray where supply reliability, contracting, or clinical familiarity outweighs price differences.
What patent litigation and Paragraph IV challenges affect Optiray 300?
No major, currently market-defining Paragraph IV litigation is broadly associated with Optiray 300. That is consistent with the product’s age and the apparent absence of a valuable current patent barrier.
Any future dispute would more likely concern:
- A specific generic ioversol approval.
- A manufacturing process.
- A delivery device.
- A packaging configuration.
- Labeling or method-of-use language.
- Contractual or supply arrangements.
Patent litigation is therefore a secondary risk. Regulatory approval, manufacturing reliability, and commercial contracting are more important determinants of competitive entry.
How does Optiray 300 compare with Omnipaque 300 and Isovue 300?
| Factor |
Optiray 300 |
Omnipaque 300 |
Isovue 300 |
| Active ingredient |
Ioversol |
Iohexol |
Iopamidol |
| Manufacturer |
Guerbet |
GE HealthCare |
Bracco |
| Product maturity |
Mature |
Mature |
Mature |
| Patent-based protection |
Limited |
Limited for core product |
Limited for core product |
| Key advantage |
Established ioversol supply and portfolio position |
Broad institutional adoption and global scale |
Established hospital and imaging-center use |
| Main risk |
Price and substitution |
Supply disruption and contracting |
Price competition and multi-source substitution |
| Demand driver |
Imaging procedure volume |
Imaging procedure volume |
Imaging procedure volume |
These products compete more on supply, contracts, workflow, and price than on patent differentiation. Clinical substitution is possible in many settings, but institutional protocols may limit rapid switching.
What is the investment and licensing outlook for Optiray 300?
Optiray 300 is unlikely to command the valuation profile of a protected specialty medicine. Its value is tied to durable cash generation, manufacturing assets, customer contracts, and portfolio synergies.
A licensing or acquisition analysis should focus on:
- Net realized price after rebates.
- Hospital contract duration.
- Share of Guerbet’s U.S. contrast revenue.
- Gross margin by presentation.
- Manufacturing-site concentration.
- FDA inspection history.
- Supply interruption frequency.
- Generic approvals and abbreviated new drug applications.
- Exposure to large group purchasing organizations.
- Product switching costs.
The asset may be strategically valuable as part of a broader contrast-media portfolio, but standalone upside is limited without a new delivery system, differentiated presentation, geographic expansion, or supply-based share gains.
Key Takeaways
- Optiray 300 is a mature ioversol-based injectable contrast agent.
- Its practical exclusivity has ended, and no broad current patent moat is apparent.
- Revenue is driven by imaging procedure volumes, hospital contracts, pricing, and supply reliability.
- Guerbet does not publicly disclose standalone Optiray 300 revenue.
- Generic and therapeutic-substitution risks are high, but sterile manufacturing limits the number of credible entrants.
- The product competes directly with Omnipaque 300, Isovue 300, Ultravist, and other iodinated contrast agents.
- Manufacturing resilience and hospital contracting are more important than patent litigation.
- Financial performance is likely stable to declining on a standalone basis, with temporary upside during competitor supply disruptions.
- The product’s strongest strategic value is as part of a broader contrast-media portfolio.
FAQs
Is Optiray 300 still marketed in the United States?
Yes. Optiray 300 remains an FDA-approved ioversol injection product associated with Guerbet’s contrast-media portfolio.
Is Optiray 300 a generic drug?
Optiray 300 is a branded product. It competes in a mature market where generic or alternative iodinated contrast products can be approved and substituted.
Who manufactures Optiray 300?
Guerbet is the principal company associated with the Optiray franchise in the United States. Manufacturing and marketing arrangements can vary by jurisdiction and presentation.
Does Optiray 300 have biosimilar risk?
No. Biosimilar regulation applies to biologic products. Optiray 300 is a synthetic small-molecule injectable. Its competitive risks are generic entry and substitution by other nonionic iodinated contrast agents.
Can hospitals substitute Omnipaque 300 or Isovue 300 for Optiray 300?
Substitution may be clinically and operationally possible, but hospitals generally assess imaging protocols, concentration, injector compatibility, formulary policies, supply, and contract terms before changing products.
References
-
Guerbet. (2023). Universal registration document and annual financial report 2023. Guerbet.
-
U.S. Food and Drug Administration. (2022). A contrast media shortage information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Optiray 300 prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
DailyMed. (n.d.). Optiray 300 (ioversol injection) labeling. National Library of Medicine.
